Search company, investor...
Polyplus company logo


Founded Year



Acq - Fin - II | Alive

Total Raised




Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+40 points in the past 30 days

About Polyplus

Polyplus operates as a biotechnology company. It develops and sells solutions for the delivery of nucleic acids in research, bioproduction, and therapeutics. The company also supplies a wide range of reagents for the transfection of genes, oligonucleotides, and siRNA. It was founded in 2001 and is based in Illkirch-Strasbourg, France. In February 2020, Polyplus was acquired by Warburg Pincus.

Headquarters Location

850 bd Sebastien Brant

Illkirch-Strasbourg, 67400,


33 (0)3 90 40 61 80

Missing: Polyplus's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Polyplus's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Polyplus

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Polyplus is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Polyplus Patents

Polyplus has filed 23 patents.

The 3 most popular patent topics include:

  • Battery (electricity)
  • Energy storage
  • Lithium-ion batteries
patents chart

Application Date

Grant Date


Related Topics




Computer buses, Fluid dynamics, Thermoplastics, Polymers, Type 1936A-class destroyers


Application Date


Grant Date



Related Topics

Computer buses, Fluid dynamics, Thermoplastics, Polymers, Type 1936A-class destroyers



Latest Polyplus News

Polyplus Introduces LipidBrick for LNP Formulation in mRNA Therapeutics

Mar 15, 2023

LipidBrick IM21.7c broadens the scope of LNP usage in various applications from prophylactic vaccines to therapeutic and oncology applications. 03.15.23 Polyplus, a solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, introduced a novel cationic lipid for lipid nanoparticle (LNP) formulation in mRNA therapeutic and vaccine development. LipidBrick IM21.7c, broadens the scope of LNP usage in various applications from prophylactic vaccines to therapeutic and oncology applications. LipidBrick IM21.7c overcomes current generation ionizable lipid challenges used in LNP’s, by enabling a wider in vivo biodistribution and decreasing accumulation in the liver. Proof of concept work has demonstrated that due to LipidBrick IM21.7c’s intrinsic properties in modulating the overall charge of LNP’s, it improves drug efficiency and formulation stability without safety issue. “Polyplus draws on over 20 years legacy in cationic polymer and lipid-based delivery systems for both in vitro and in vivo models to power mRNA therapeutics, said Mario Philips, CEO. “As we carry forward this legacy, we are working to ensure that our offer opens new possibilities to improve LNP formulation to meet the growing demand of the mRNA therapeutic market. LipidBrick IM21.7c is already used in jetMESSENGER and liposomal formulations for mRNA delivery, as a ready-to-use solution that requires no onsite formulation.” Julien Depollier, strategic partnership director said: “In addition, RNA vaccine producers are looking for lipids without intellectual property (IP) constraints. Polyplus has an independent IP on LipidBrick IM21.7c and its imidazolium family of cationic lipid which allows simpler and more cost-effective contracts for direct developers and manufacturers to leverage their offer,” Julien Depollier, Strategic Partnership Director commented. The new LipidBrick IM21.7c will be made available in April 2023.

Polyplus Frequently Asked Questions (FAQ)

  • When was Polyplus founded?

    Polyplus was founded in 2001.

  • Where is Polyplus's headquarters?

    Polyplus's headquarters is located at 850 bd Sebastien Brant, Illkirch-Strasbourg.

  • What is Polyplus's latest funding round?

    Polyplus's latest funding round is Acq - Fin - II.

  • How much did Polyplus raise?

    Polyplus raised a total of $3.24M.

  • Who are the investors of Polyplus?

    Investors of Polyplus include Warburg Pincus, ArchiMed, Sudinnova, CIC Finance, CIC Vizille Capital Innovation and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.